XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Stock Plans (Tables)
 3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Compensation Expense
Stock compensation expense, included in Selling, general and administrative expense in the unaudited Condensed Consolidated Statements of Income, is as follows:
 Three Months Ended March 31,
(In thousands)20252024
Stock compensation expense$2,629 $4,187 
Income tax benefit649 1,026 
Stock compensation expense, net of tax$1,980 $3,161 
We have not capitalized any stock-based compensation expense.
Summary of Stock Option Activity
A summary of stock option activity for the three months ended March 31, 2025, is as follows:
SharesWeighted Average
Exercise Price
Outstanding at January 1, 202515,018 $45.10 
Exercised(5,173)44.50 
Outstanding and exercisable at March 31, 20259,845 $45.41 
Summary of Restricted Stock and Unit Activity A summary of restricted stock activity for the three months ended March 31, 2025, is as follows:
SharesWeighted Average
Grant Date
Fair Value
Unvested at January 1, 2025179,584 $150.39 
Granted55,124 159.70 
Vested(31,277)138.81 
Forfeited(7,648)153.94 
Unvested at March 31, 2025195,783 $154.72 
Schedule of Fair Value Assumptions for Units The following weighted average assumptions were used in estimating the fair value of the performance stock units granted in the first quarter of 2025.
Fair value per unit$160.54
Risk-free interest rate4.28%
Expected dividend yield1.14%
Expected volatility25.3%
MSA stock beta0.744
Summary of Performance Stock Unit Activity
A summary of performance stock unit activity for the three months ended March 31, 2025, is as follows:
SharesWeighted Average
Grant Date
Fair Value
Unvested at January 1, 2025161,996 $146.50 
Granted55,405 160.54 
Performance adjustments(a)
64,457 143.49 
Vested(118,605)143.47 
Forfeited(15,852)154.55 
Unvested at March 31, 2025147,401 $152.03 
(a)Performance adjustments relate primarily to the final number of shares issued for the 2022 performance unit awards which vested in the first quarter of 2025 at 220% of the target award based on both cumulative performance against EBITDA margin and revenue growth targets and MSA's total shareholder return during the three-year performance period.